NCT06549972Completed
Predictive Role of KLK10 and Other Neuroinflammatory Molecules on Clinical Outcomes of AIS
Predictive Role of Early Blood KLK10 and Other Neuroinflammatory Molecules on Clinical Outcomes of Acute Ischemic Stroke
Source: ClinicalTrials.gov · Last updated 29 Jul 2025
Brief summary (registry, in English)
This study aims to investigate the dynamic changes and differential expression characteristics of neuroinflammatory molecules such as kallikrein-related peptidase 10 (KLK10), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), and glial fibrillary acidic protein (GFAP) in the plasma of patients with first-ever anterior circulation acute ischemic stroke (AIS). It will analyze the correlation between these molecules and the severity of neurological deficits, infarct volume, brain edema, hemorrhagic transformation, progressive stroke, and clinical outcomes at three months. The goal is to assess the predictive value of these molecules for AIS prognosis, guiding early treatment and new molecular targets for prevention and treatment.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 273 (actual)
- First submitted
- 6 Aug 2024
- Start date
- 12 Aug 2024
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Ruijin Hospital
- Diseases
- Stroke
- NCT number
- NCT06549972
What you commit to
- Study type: Observational
- Participants enrolled: 273
- From 12 Aug 2024 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Ongoing anti-inflammatory drug treatment.
Other illness
- Intracranial hemorrhage;
- Stroke with unknown onset time;
- Malignant tumors;
- Hematologic disorders;
- Recent myocardial infarction (less than 3 months);
Other
- Pregnancy;
- Severe liver or kidney dysfunction;
Who the study is looking for
- for AIS patients:
- Selection of 182 patients with first-ever acute ischemic stroke (AIS) who are hospitalized at our hospital, aged ≥18 years, with no restriction on gender;
- Patients must be admitted within 24 hours of the onset of AIS;
- Diagnosis must be confirmed by cranial magnetic resonance imaging (MRI) or computed tomography (CT);
- All enrolled patients must provide written informed consent.
- for healthy controls:
- Age and gender-matched;
- No organic diseases;
- Written informed consent must be signed
Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Neurology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.